By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Precision Therapeutics, Inc. 

2516 Jane Street

Pittsburgh  Pennsylvania  15203  U.S.A.
Phone: 1-866-CHEMOFX (1-866-243-6639) Fax: 1-866-243-2424


SEARCH JOBS


Industry
Pharmaceutical






Company News
CEO Departs Pittsburgh-Based Cancer Diagnostics Firm Precision Therapeutics, Inc. 10/7/2014 6:48:12 AM
Precision Therapeutics, Inc. Release: Manuscript Demonstrating Chemofx Is A Predictive Marker In Ovarian Cancer Published By The British Journal Of Cancer 7/22/2014 10:57:45 AM
Precision Therapeutics, Inc. Supports The Annual National Ovarian Cancer Coalition (NOCC) Run/Walk To Break The Silence 7/17/2014 11:17:35 AM
Precision Therapeutics, Inc. Release: Two Pivotal Manuscripts On ChemoFx Accepted For Publication 6/26/2014 11:05:57 AM
Precision Therapeutics, Inc. Release: Data Demonstrating The Ability Of Chemofx® To Identify Platinum-Resistant Primary Ovarian Cancer Patients Prior To Treatment Published ByThe American Journal Of Obstetrics And Gynecology 2/24/2014 8:23:29 AM
Precision Therapeutics, Inc. Uses Automated Method To Extract RNA For Use In The GeneFx® Colon Signature 12/16/2013 8:21:39 AM
Precision Therapeutics, Inc. Presents Clinical Data Showing the ChemoFx® Drug Response Test Has Predictive Value in Recurrent Epithelial Ovarian Cancer 11/5/2013 10:14:37 AM
Precision Therapeutics, Inc. Presents Clinical Data Showing the ChemoFx® Drug Response Test Has Predictive Value in Recurrent Epithelial Ovarian Cancer 11/5/2013 7:38:33 AM
Precision Therapeutics, Inc. Announces Unparalleled Results That Show Recurrent Ovarian Cancer Patients Live 65% Longer in Breakthrough Prospective Clinical Trial 8/19/2013 9:26:50 AM
Precision Therapeutics, Inc. Release: ChemoFx® Chemoresponse Assay Identifies Platinum-Resistance in Primary Ovarian Cancer Patients 7/8/2013 10:15:17 AM
123456
//-->